Supplemental Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

Key Points

• Preclinical activity indicates that datopotamab deruxtecan effectively targets TROP2 in endometrial carcinoma types.
• Flow cytometry analysis shows characteristic histograms of primary endometrial carcinoma cell lines used in the assessment.
• The methodology involved examining primary EC cell lines to evaluate therapeutic responses to the antibody-drug conjugate.
• These findings suggest potential clinical applications for Dato-DXd in treating poorly differentiated endometrial carcinomas.

Abstract